RE Dickinson Investment Advisors’s NovoCure NVCR Stock Holding History

RE Dickinson Investment Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-34	Closed	-$1K	–	262
2023 Q3	$1K	Hold	34	–	–	﹤0.01%	256
2023 Q2	$1K	Hold	34	–	–	﹤0.01%	368
2023 Q1	$2K	Hold	34	–	–	﹤0.01%	370
2022 Q4	$2K	Hold	34	–	–	﹤0.01%	347
2022 Q3	$3K	Hold	34	–	–	﹤0.01%	204
2022 Q2	$2	Hold	34	–	–	﹤0.01%	255
2022 Q1	$3K	Sell	34 -15	-31%	-$1.1K	﹤0.01%	247
2021 Q4	$3K	Buy	+49	New	+$4.92K	﹤0.01%	243

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

RE Dickinson Investment Advisors's NVCR Position: Q4 2023 in Review

RE Dickinson Investment Advisors sold out of NovoCure (NVCR) in Q4 2023, closing a stake of 34 shares — an estimated $1K sold.

RE Dickinson Investment Advisors first reported a position in NVCR in Q4 2021 and held it in 8 quarters. The position peaked at $3K in Q3 2022. 219 funds tracked by Wall St. Rank hold NVCR as of Q4 2023.

RE Dickinson Investment Advisors reported no remaining NovoCure position as of Q4 2023 after selling out during the quarter.
RE Dickinson Investment Advisors sold 34 NovoCure shares in Q4 2023, an estimated $1K.
RE Dickinson Investment Advisors first reported a position in NovoCure in Q4 2021 and held it in 8 quarters.
RE Dickinson Investment Advisors's NovoCure position peaked at $3K in Q3 2022.
219 funds tracked by Wall St. Rank held NovoCure as of Q4 2023.

Based on RE Dickinson Investment Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.